AKT1 and non-small cell lung carcinoma: Our laboratory has recently provided evidence of a synergistic interaction between sorafenib and erlotinib or between sorafenib and cetuximab, a monoclonal antibody targeting the extracellular domain of the EGF receptor, in a panel of NSCLC and colorectal cancer (CRC) cell lines, in vitro and in vivo, which is accompanied by a marked and sustained inhibition of the MAPK- and AKT-dependent intracellular signals [11].